Join Mapi Pharma’s management team for a virtual key opinion leader (KOL) event featuring Aaron Miller, MD (Corinne Dickinson Center for Multiple Sclerosis, Icahn School of Medicine, Mount Sinai) and Carlo S. Tornatore, MD (MedStar Health, MedStar Georgetown University Hospital), who will discuss the unmet needs and current treatment landscape for Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Forms of Multiple Sclerosis (RMS) based on Mapi’s Depot technology and IP.

The event will include an overview of Mapi’s Glatiramer Acetate Depot (GA Depot), a once-monthly injection for the treatment of patients with multiple sclerosis and the company’s Depot technologies and development infrastructure from R&D to commercial supply. GA Depot is currently the subject of clinical studies for both relapsing forms of MS (RMS) presently in a final review process in Germany and is starting a global Phase III study for PPMS. Company management will review results from the successful multi-center Phase II clinical trial of GA Depot for PPMS with support from the excellent Phase III data from the RMS study. The recent PPMS results were presented at the ACTRIMS Forum 2026. Management will discuss next registration steps and commercial opportunities for both indications and unmet clinical needs.

A live question and answer session will follow the formal presentations.